Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVGBM
- Development stage
- Phase 1
- Lead developer
- CureVac
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
CVGBM is an investigational therapeutic mRNA-based cancer vaccine developed by CureVac (acquired by BioNTech) for the treatment of glioblastoma (GBM). The vaccine consists of nucleotide-unmodified mRNA encapsulated in lipid nanoparticles (LNPs). It encodes a fusion protein containing eight epitopes derived from tumor-associated antigens (TAAs) that are over-presented in GBM, including five restricted to HLA-A*02:01 and three restricted to various HLA-DR alleles. CVGBM is designed to induce both CD8+ and CD4+ T-cell responses against the tumor. It is currently being evaluated in Phase 1 clinical trials (NCT05938387) for patients with newly diagnosed, surgically resected, MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of unmethylated GBM.
- Other names
- CV09050101 mRNA vaccineCV-09050101 mRNA vaccineCV 09050101 mRNA vaccine
Beyond the preview
Go deeper on CVGBM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVGBM.